STAT Plus: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector
WASHINGTON — Since the Treasury Department unveiled a proposal to curb U.S. investment in Chinese biotech firms last week, stakeholders nationwide are debating the likely impact of these restrictions.
The central discussion has centered on whether such limits are necessary. Should the focus be on accelerating domestic R&D to gain a competitive edge, or on preventing Chinese biotechs from closing the gap? And is it realistically possible to slow China’s biotech advancement?
Attention now shifts to the rule’s actual effects. The proposal is more stringent than many expected, though a Treasury official indicated that licensing arrangements would remain exempt—a nuance that lies at the heart of ongoing disagreements about its ramifications.
Also Read
- Hospital Antibiotic Cefepime Linked to Rare Delusion of Being Dead in Elderly Renal Patient
- Medicare Stand-Alone Drug Plans Face Premium Hikes Amid Mixed Messages on Prescription Costs
- Lyme Vaccine Data at IDWeek Show Protection Was Measured Only After Four Doses Across Two Tick Seasons
- Access to Emergency Supplies Remains Out of Reach for Vulnerable Communities